Phase 1 study of TRU-015, a CD20-directed small modular immunopharmaceutical (SMIP™) protein therapeutic, in subjects with rheumatoid arthritis

por Burge, DJ, Bookbinder, SA, Kivitz, AJ, Fleischmann, RM, Shu, C, Bannink, J, Barone, D
Publicado 2007

TRU-015, a small modular immunopharmaceutical (SMIP™) drug candidate directed against CD20, demonstrates clinical improvement in subjects with rheumatoid arthritis

por Burge, DJ, Shu, C, Martin, RW, Littlejohn, TW, Wallace, DJ, Taborn, J, Palmer, WR, Kivitz, A
Publicado 2007